ESTRO 2022 - Abstract Book

S362

Abstract book

ESTRO 2022

Results 509 patients were included in the interim analysis. Main circumstances of prescription were HRL (38.8%) and MS (28.1%). Main baseline parameters by circumstance of prescription are presented in Table (except for ‘other circumstance’, 21 patients (4.5%)). Gleason score ≥ 4+3 was particularly frequent in HRL (77.2%) and MS (78.8%) subgroups.

Conclusion

Main reasons of choice of planned total duration of triptorelin treatment differed between subgroups of circumstances of prescription. First reason was adapted to PCa stage: Gleason score for high risk PCa (49.4% in HRL and 32.4% in LA), PSA level (28.6%) for BCR, number of bone metastases (35.5%) for MS. Tumor aggressiveness seems to be the main driver of choice, with parameter adapted to the stage.

PD-0418 Resect or Preserve? Comparing treatment strategies in clinically node positive bladder cancer

M. Swinton 1 , N.B.G. Mariam 1 , J.L. Tan 2 , L. Afferi 3 , C. Lonati 4 , M. Moshini 5 , M. Lau 6 , V. Ramani 6 , V. Sangar 6 , N. Clarke 6 , H. Mistry 7 , T. Elumalai 8 , P. Hoskin 1 , A. Choudhury 1 1 Christie Hospital, Clinical Oncology, Manchester, United Kingdom; 2 University of Manchester, Division of Medical Education, Manchester, United Kingdom; 3 Luzerner Kantonsspital, Department of Urology, Lucerne, Switzerland; 4 Spedali Civili of Brescia, Department of Urology, Brescia, Italy; 5 Urological Research Institute, IRCCS Ospedale San Raffaele, Division of Experimental Oncology/Unit of Urology, Milan, Italy; 6 Christie Hospital, Urology, Manchester, United Kingdom; 7 Christie Hospital, Pharmacy and Cancer Sciences, Manchester, United Kingdom; 8 Addenbrooke's Hospital, Clinical Oncology, Cambridge, United Kingdom Purpose or Objective Worldwide there is wide variation in the management of patients with clinically node positive non-metastatic (cN+M0) bladder cancer. There is a paucity of high-quality evidence to guide practice. In many European centres, primary management of fit patients is radical surgery often preceded by platinum-based chemotherapy. In the UK in contrast, radical radiotherapy (RT) – a bladder-preserving treatment - is also offered as an alternative treatment to surgery. To aid clinician and patient decision making, an international multi-centre retrospective analysis was undertaken to assess clinical outcomes for cN+M0 bladder cancer receiving radical treatment. Materials and Methods Data on an international cohort of patients receiving surgery from 2007-2020 for cN+M0 bladder cancer was collated by sending data collection forms to a number of participating European Medical Centres in France, Italy, the Netherlands and Russia. Data was collected on a second cohort of cN+M0 bladder patients diagnosed at a large tertiary cancer centre in the UK from 2013-2020. Data was collected on treatment received, clinical outcomes and patient and tumour factors. Overall survival (OS) was calculated using date of TURBT as t=0. Kaplan-Meier curves for OS were produced for 3 cohorts ‘International’ patients receiving surgery, patients at the UK centre receiving surgery and UK patients receiving RT.